LeMaitre Vascular, Inc. (NASDAQ:LMAT) Receives Consensus Recommendation of "Hold" from Brokerages

LeMaitre Vascular, Inc. (NASDAQ:LMAT - Get Free Report) has received a consensus recommendation of "Hold" from the six research firms that are presently covering the firm, MarketBeat.com reports. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $97.83.

Separately, Barrington Research reissued a "market perform" rating on shares of LeMaitre Vascular in a research note on Tuesday.

LeMaitre Vascular Price Performance

Shares of LeMaitre Vascular stock traded up $1.00 on Tuesday, reaching $80.82. 48,388 shares of the stock were exchanged, compared to its average volume of 168,445. The firm's 50 day moving average is $82.76 and its 200-day moving average is $87.63. The firm has a market cap of $1.83 billion, a PE ratio of 40.82, a P/E/G ratio of 2.10 and a beta of 0.82. LeMaitre Vascular has a one year low of $71.42 and a one year high of $109.58. The company has a debt-to-equity ratio of 0.48, a quick ratio of 13.83 and a current ratio of 16.49.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last posted its earnings results on Thursday, May 1st. The medical instruments supplier reported $0.48 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.02). The business had revenue of $59.87 million for the quarter, compared to analyst estimates of $57.61 million. LeMaitre Vascular had a return on equity of 13.53% and a net margin of 19.96%. The firm's quarterly revenue was up 12.0% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.44 earnings per share. As a group, analysts anticipate that LeMaitre Vascular will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, May 29th. Shareholders of record on Thursday, May 15th were paid a $0.20 dividend. The ex-dividend date of this dividend was Thursday, May 15th. This represents a $0.80 dividend on an annualized basis and a yield of 0.99%. LeMaitre Vascular's payout ratio is presently 40.40%.

Insider Transactions at LeMaitre Vascular

In related news, CEO George W. Lemaitre sold 4,399 shares of LeMaitre Vascular stock in a transaction dated Tuesday, May 20th. The stock was sold at an average price of $85.10, for a total value of $374,354.90. Following the completion of the transaction, the chief executive officer owned 1,827,003 shares in the company, valued at approximately $155,477,955.30. This trade represents a 0.24% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In the last ninety days, insiders sold 100,000 shares of company stock valued at $8,556,857. Corporate insiders own 9.50% of the company's stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Principal Financial Group Inc. raised its stake in LeMaitre Vascular by 3.0% in the first quarter. Principal Financial Group Inc. now owns 111,865 shares of the medical instruments supplier's stock worth $9,385,000 after buying an additional 3,248 shares in the last quarter. Invesco Ltd. increased its position in shares of LeMaitre Vascular by 50.5% in the 4th quarter. Invesco Ltd. now owns 174,998 shares of the medical instruments supplier's stock valued at $16,124,000 after acquiring an additional 58,720 shares during the period. Compass Planning Associates Inc increased its position in shares of LeMaitre Vascular by 91.4% in the 1st quarter. Compass Planning Associates Inc now owns 11,776 shares of the medical instruments supplier's stock valued at $988,000 after acquiring an additional 5,623 shares during the period. Johnson Investment Counsel Inc. boosted its holdings in shares of LeMaitre Vascular by 34.8% in the 1st quarter. Johnson Investment Counsel Inc. now owns 29,428 shares of the medical instruments supplier's stock valued at $2,469,000 after acquiring an additional 7,603 shares during the last quarter. Finally, Consolidated Planning Corp acquired a new stake in LeMaitre Vascular during the 1st quarter worth about $947,000. Hedge funds and other institutional investors own 84.64% of the company's stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.